Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VeraSeal Fibrin Sealant Alongside TXA in Total Knee Replacement
NCT07455591Phase 4Completed
- Sponsor
- Singapore General Hospital
- Start
- Jan 2024
- Primary completion
- Aug 2024
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of Fibrinogen human in osteoarthritis (OA) (2 arms), sponsored by Singapore General Hospital. Primary endpoints: Serum Hemoglobin at 1 day, Knee Flexion Range of Motion at 1 day and 3 more. Started Jan 2024; status: completed.
02
Drugs
Fibrinogen human
03
Conditions
osteoarthritis (OA)
Beyond the preview
Go deeper on NCT07455591.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07455591.